Seamus Fernandez

how are you looking at the impact of the current antifibrotic standard of care and the dropout rate

what are the key risks as we evaluate Phase II to Phase III -- and how do you see the opportunity

Just wondering if you could help us position the areas that you see the most kind of relative upside

do you actually think that this is a sustainable sort of margin threshold within the context of Bristol-Myers Squibb

if that relative comp continues to be sort of a focus point for Bristol right now

where you think novel oral drugs like iberdomide or resignomide could appropriately fit within the context of the overall multiple myeloma market

I was hoping you could talk about the patient experience that you're seeing so far in the field

how the market as you see it is starting to segment and could segment going forward

just wondering why you couldn't attack immunology broadly in the same way as you have obesity, investing earlier, faster, and more aggressively

how the competitors' dynamics are playing out and how you, Dave and Dan see the market evolving from here

hoping, Dave, you could discuss a little bit more your views on the path for price with orforglipron and the growing number of assets coming to market

How is Ebglyss tracking against your ambition of it being a best in class launch? Is your vision for peak sales in line with consensus sales of $2 billion